%0 Journal Article %A Ruwandi M. Kariyawasam %A Tanis C. Dingle %A Brittany E. Kula %A Wendy I. Sligl %A Ilan S. Schwartz %T COVID-19 Associated Pulmonary Aspergillosis: Systematic Review and Patient-Level Meta-analysis %D 2021 %R 10.1101/2021.05.21.21257626 %J medRxiv %P 2021.05.21.21257626 %X Rationale Pulmonary aspergillosis may complicate COVID-19 and contribute to excess mortality in intensive care unit (ICU) patients. The incidence is unclear because of discordant definitions across studies.Objective We sought to review the incidence, diagnosis, treatment, and outcomes of COVID-19-associated pulmonary aspergillosis (CAPA), and compare research definitions.Methods We systematically reviewed the literature for ICU cohort studies and case series including ≥ patients with CAPA. We calculated pooled incidence. Patients with sufficient clinical details were reclassified according to 4 standardized definitions (Verweij, White, Koehler, and Bassetti).Measurements Correlations between definitions were assessed with Spearman’s rank test. Associations between antifungals and outcome were assessed with Fisher’s Exact test.Main Results 38 studies (35 cohort studies and 3 case series) were included. Among 3,297 COVID-19 patients in ICU cohort studies, 313 were diagnosed with CAPA (pooled incidence 9.5%). 197 patients had patient-level data allowing reclassification. Definitions had limited correlation with one another (ρ=0.330 to 0.621, p<0.001). 38.6% of patients reported to have CAPA did not fulfil any research definitions. Patients were diagnosed after a median of 9 days (interquartile range 5-14) in ICUs. Tracheobronchitis occured in 5.3% of patients examined with bronchoscopy. The mortality rate (50.0%) was high, irrespective of antifungal use (p=0.28); this remained true even when the analysis was restricted to patients meeting standardized definitions for CAPA.Conclusions The reported incidence of CAPA is exaggerated by use of non-standard definitions. Further research should focus on identifying patients likely to benefit from antifungals.Competing Interest StatementISS received personal fees from AVIR Pharma, outside the submitted work. TCD has received research grant funding from AVIR Pharma and clinical trial support from BioMerieux, outside the submitted work. All other authors declare no conflicts.Funding StatementThis study was unfunded.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNot applicable; review of published data %U https://www.medrxiv.org/content/medrxiv/early/2021/05/24/2021.05.21.21257626.full.pdf